专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018237341A1 A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY 审中-公开
公开(公告)号：WO2018237341A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/039120
申请日：2018-06-22
申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY , DCB-USA LLC
发明人： WU, Chia-Cheng , LIN, Tzu-Yin , HUANG, Chao-Yang , CHEN, Yu-Jung , YU, Jei-Hwa , CHIEN, Chen-Li
IPC分类号： A61K39/395 , C07K16/18 , C07K16/00 , C07K16/28 , C07K16/46 , C07K16/30
摘要： An asymmetric heterodimeric antibody includes a knob structure formed in a CH3 domain of a first heavy chain; a hole structure formed in a CH3 domain of a second heavy chain, wherein the hole structure is configured to accommodate the knob structure so that a heterodimeric antibody is formed; and a T-cell targeting domain fused to the CH3 domain of the first heavy chain or the second heavy chain, wherein the T-cell targeting domain binds specifically to an antigen on the T-cell. The T-cell targeting domain is a ScFv or Fab derived from an anti-CD3 antibody. The asymmetric heterodimeric antibody may have L234A and L235A mutations or L235A and G237A such that its effector binding is compromised.

2. 发明申请

WO2018017863A1 MODIFIED ANTIGEN-BINDING FAB FRAGMENTS AND ANTIGEN-BINDING MOLECULES COMPRISING THE SAME 审中-公开
标题翻译：修饰的抗结合FAB片段和包含该抗体的抗结合分子
公开(公告)号：WO2018017863A1
公开(公告)日：2018-01-25
申请号：PCT/US2017/043126
申请日：2017-07-20
申请人： DCB-USA LLC , DEVELOPMENT CENTER FOR BIOTECHNOLOGY
发明人： HU, Chih-Yung , HUANG, Chao-Yang , CHEN, Yu-Jung , WU, Chia-Cheng , KUAN, Chien-Tsun , LO, Chia-Hsiang , TSAI, Hsien-Yu
IPC分类号： A61K39/395 , C07K16/46 , C12N15/62 , C12N15/64 , C12N15/66 , C12N15/86
摘要： The present invention provides a modified antigen-binding Fab fragment. An antigen-binding molecule comprising the antigen-binding Fab fragment and a composition comprising the molecule are also provided.
摘要翻译：本发明提供了修饰的抗原结合性Fab片段。还提供了包含抗原结合性Fab片段的抗原结合分子和包含该分子的组合物。

3. 发明申请

WO2014172591A3 HUMANIZED ANTIBODY AGAINST INTERLEUKIN-20 AND TREATMENT FOR INFLAMMATORY DISEASES 审中-公开
标题翻译：人源化抗IL-20抗体及治疗炎症性疾病
公开(公告)号：WO2014172591A3
公开(公告)日：2014-10-23
申请号：PCT/US2014/034579
申请日：2014-04-18
申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY , DCB-USA LLC
发明人： WU, Chia-Cheng , HUANG, Chao-Yang , LIN, Yu-Ying , CHEN, Yu-Jung , LAI, Jiann-Shiun
IPC分类号： C07K16/46
摘要： A humanized antibody, or a scFv, Fab, or F(ab') 2 thereof, includes: a heavy chain variable region, or a homologous variant thereof, wherein the heavy chain variable region includes: heavy chain framework regions, CDRH1 that has the sequence of SEQ ID NO:19, CDRH2 that has the sequence of SEQ ID NO:20, and CDRH3 that has the sequence of SEQ ID NO:21, wherein the heavy chain variable region and the homologous variant share at least 90% sequence identity in the heavy chain framework regions; and a light chain variable region, or a homologous variant thereof, that includes: light chain framework regions, CDRL1 that has the sequence of SEQ ID NO:22, CDRL2 that has the sequences of SEQ ID NO:23, and CDRL3 that has the sequences of SEQ ID NO:24, wherein the light chain variable region and the homologous variant share at least 90% sequence identity in the light chain framework regions.
摘要翻译：人源化抗体或其scFv，Fab或F（ab'）2包括：重链可变区或其同源变体，其中所述人源化抗体或其scFv，Fab或F 重链可变区包括：重链框架区，具有SEQ ID NO：19的序列的CDRH1，具有SEQ ID NO：20的序列的CDRH2和具有SEQ ID NO：21的序列的CDRH3，其中所述重链可变区和同源变体在重链框架区中具有至少90％的序列同一性; 和轻链可变区或其同源变体，其包含：轻链构架区，具有SEQ ID NO：22序列的CDRL1，具有SEQ ID NO：23序列的CDRL2和具有SEQ ID NO：23序列的CDRL3 SEQ ID NO：24的序列，其中轻链可变区和同源变体在轻链框架区中具有至少90％的序列同一性。

4. 发明申请

WO2018237364A1 ASYMMETRIC HETERODIMERIC FC-SCFV FUSION ANTI-GLOBO H AND ANTI-CD3 BISPECIFC ANTIBODY AND USES THEREOF IN CANER THERAPY 审中-公开
公开(公告)号：WO2018237364A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/039170
申请日：2018-06-22
申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY , DCB-USA LLC
发明人： WU, Chia-Cheng , LIN, Tzu-Yin , CHEN, Yu-Jung , HUANG, Chao-Yang
IPC分类号： C07K16/18 , A61K39/395 , A61P35/00 , C07K16/28 , C07K16/40
摘要： A bispecific anti-Globo H antibody includes an anti-Globo H antibody that binds specifically to Globo H; and a T-cell targeting domain fused to a CH3 domain of a heavy chain of the anti-Globo H antibody, wherein the T-cell targeting domain binds specifically to an antigen on T-cells; and wherein the anti-Globo H antibody comprises mutations at an effector binding site such that the bispecific anti-Globo H antibody has a diminished effector function. The T-cell targeting domain is a ScFv or Fab from an anti-CD3 antibody.

5. 发明申请

WO2018218068A1 HUMANIZED ANTIBODIES AGAINST GLOBO H AND USES THEREOF IN CANCER TREATMENTS 审中-公开
公开(公告)号：WO2018218068A1
公开(公告)日：2018-11-29
申请号：PCT/US2018/034469
申请日：2018-05-24
申请人： DEVELOPMENT CENTER FOR BIOTECHNOLOGY , DCB-USA LLC
发明人： WU, Chia-Cheng , LAI, Szu-Liang , CHEN, Yu-Jung , HU, Chih-Yung , LIN, Tzu-Yin
IPC分类号： A61K39/395 , C07K16/30 , C07K16/44
摘要： A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDRl, HCDR2, and HCDR3 and a light -chain variable domain having three complementary regions consisting of LCDRl, LCDR2, and LCDR3, wherein the sequence of HCDRl is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDRl is KSNQNLLX' SGNRRYZLV (SEQ ID NO: 7, wherein X' is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).

6. 发明公开

EP3487532A1 MODIFIED ANTIGEN-BINDING FAB FRAGMENTS AND ANTIGEN-BINDING MOLECULES COMPRISING THE SAME 审中-公开
公开(公告)号：EP3487532A1
公开(公告)日：2019-05-29
申请号：EP17831887.9
申请日：2017-07-20
申请人： DCB-USA LLC , Development Center for Biotechnology
发明人： HU, Chih-Yung , HUANG, Chao-Yang , CHEN, Yu-Jung , WU, Chia-Cheng , KUAN, Chien-Tsun , LO, Chia-Hsiang , TSAI, Hsien-Yu
IPC分类号： A61K39/395 , C07K16/46 , C12N15/62 , C12N15/64 , C12N15/66 , C12N15/86

7. 发明公开

EP2986640A2 HUMANIZED ANTIBODY AGAINST INTERLEUKIN-20 AND TREATMENT FOR INFLAMMATORY DISEASES 有权
标题翻译：人源化抗体靶向白细胞介素20和治疗炎症性疾病
公开(公告)号：EP2986640A2
公开(公告)日：2016-02-24
申请号：EP14785612.4
申请日：2014-04-18
申请人： Development Center for Biotechnology , DCB-USA LLC
发明人： WU, Chia-Cheng , HUANG, Chao-Yang , LIN, Yu-Ying , CHEN, Yu-Jung , LAI, Jiann-Shiun
IPC分类号： C07K16/24
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： A humanized antibody, or a scFv, Fab, or F(ab')
2 thereof, includes: a heavy chain variable region, or a homologous variant thereof, wherein the heavy chain variable region includes: heavy chain framework regions, CDRH1 that has the sequence of SEQ ID NO:19, CDRH2 that has the sequence of SEQ ID NO:20, and CDRH3 that has the sequence of SEQ ID NO:21, wherein the heavy chain variable region and the homologous variant share at least 90% sequence identity in the heavy chain framework regions; and a light chain variable region, or a homologous variant thereof, that includes: light chain framework regions, CDRL1 that has the sequence of SEQ ID NO:22, CDRL2 that has the sequences of SEQ ID NO:23, and CDRL3 that has the sequences of SEQ ID NO:24, wherein the light chain variable region and the homologous variant share at least 90% sequence identity in the light chain framework regions.

8. 发明公开

EP3630182A1 HUMANIZED ANTIBODIES AGAINST GLOBO H AND USES THEREOF IN CANCER TREATMENTS 审中-公开
公开(公告)号：EP3630182A1
公开(公告)日：2020-04-08
申请号：EP18805883.8
申请日：2018-05-24
申请人： Development Center for Biotechnology
发明人： WU, Chia-Cheng , LAI, Szu-Liang , CHEN, Yu-Jung , HU, Chih-Yung , LIN, Tzu-Yin
IPC分类号： A61K39/395 , C07K16/30 , C07K16/44

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式